ADAPTIN BIO, INC. (APTN)

Adaptin Bio is a biopharmaceutical company built around a proprietary platform called the Brain Bispecific T cell Engager (BRiTE), developed at Duke University’s Department of Neurosurgery. The core innovation solves a central problem in brain cancer treatment: therapeutic molecules, including engineered immune cells, struggle to cross the blood-brain barrier and reach tumors lodged in the central nervous system. BRiTE harnesses the body’s own immune machinery—specifically T cells—and augments them to recognize and attack malignant brain cells while maintaining the ability to penetrate tissue that would normally block systemic therapeutics.

The company’s clinical focus centers on APTN-101, a BRiTE therapy targeting EGFRvIII, a mutation found on aggressive glioblastomas and other brain tumors. Preclinical work demonstrated roughly sevenfold greater brain penetration compared to conventional approaches, suggesting a possible competitive edge in treating one of oncology’s most lethal solid tumors. The molecule is positioned as a potential best-in-class candidate if clinical efficacy translates from the lab.

Adaptin Bio is a portfolio company of Lucius Partners and completed an Alternative Public Offering in April 2025, followed by a $7.7 million private placement. The company’s common stock began trading on the OTCQB Venture Market under APTN in May 2026, giving public investors access to what remains a pre-revenue clinical-stage operation. Success depends entirely on APTN-101 advancing through regulatory trials without serious safety setbacks and, later, on commercial manufacturing and market adoption in what is a small but high-need patient population for brain-directed cancer therapies.